latozinemab

News

Alector has abandoned latozinemab as a treatment for frontotemporal dementia, four years after GSK licensed the antibody in a $700m upfront deal.

News

Johnson & Johnson's 'Swiss army knife' drug Imaavy has shown efficacy in a pivotal trial involving patients with rare autoimmune disorder wAIHA.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.